Filing Flows › Fate Therapeutics (FATE) › R&D spending
Fate Therapeutics (FATE) R&D spending by quarter
Fate Therapeutics' R&D spending was $24.4M in Q2 2026 (second quarter 2026), -1% from Q1 2026. Over the last 7 quarters it ranged from $24.4M (Q2 2026) to $33.6M (Q4 2024).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $24.4M | -1% | -11% |
| Q1 2026 | $24.7M | -3% | -15% |
| Q4 2025 | $25.4M | -2% | -24% |
| Q3 2025 | $25.8M | -6% | — |
| Q2 2025 | $27.4M | -6% | — |
| Q1 2025 | $29.1M | -13% | — |
| Q4 2024 | $33.6M | — | — |
Q2 2026 at a glance
Fate Therapeutics, Q2 2026: revenue $2.1M (+9% year over year), net loss $30.2M, operating cash flow −$23.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Fate Therapeutics' R&D spending?
Fate Therapeutics' R&D spending was $24.4M in Q2 2026 (second quarter 2026), -1% from Q1 2026.
How has Fate Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $24.4M (Q2 2026) to $33.6M (Q4 2024).